Alatalo A, de Sousa Maciel I, Kucharikova N, Chew S, van Kamp I, Foraster M, Julvez J, Kanninen KM. The interaction between circulating cell-free mitochondrial DNA and inflammatory cytokines in predicting human mental health issue risk in adolescents: an explorative study. Biomedicines. 2023 Mar 7;11(3):818. doi: 10.3390/biomedicines11030818
Janssens R, Lang T, Vallejo A, Galinsky J, Plate A, Morgan K, Cabezudo E, Silvennoinen R, Coriu D, Badelita S, Irimia R, Anttonen M, Manninen RL, Schoefs E, Vandebroek M, Vanhellemont A, Delforge M, Stevens H, Simoens S, Huys I. Patient preferences for multiple myeloma treatments: a multinational qualitative study. Front Med (Lausanne). 2021 Jul 6;8:686165. doi: 10.3389/fmed.2021.686165
Carton-Garcia F, Saande CJ, Meraviglia-Crivelli D, Aldabe R, Pastor F. Oligonucleotide-based therapies for renal diseases. Biomedicines. 2021 Mar 16;9(3):303. doi: 10.3390/biomedicines9030303
Barik R, Jain S, Joshi A, Qwatra D, Tripathi GS, Goyal R. Antidiabetic activity of aqueous root extract of ichnocarpus frutescens in streptozotocin-nicotinamide induced type-II diabetes in rats. Indian J Pharmacol. 2008 Jan;40(1):19-22. doi: 10.4103/0253-7613.40484
Walker EA, Picker MJ, Granger AL, Dykstra LA. Effects of opioids in morphine-treated pigeons trained to discriminate among morphine, the low-efficacy agonist nalbuphine, and saline. J Pharmacol Exp Ther. 2004 Jul;310(1):150-8.
Allen RM, Granger AL, Dykstra LA. The competitive N-methyl-D-aspartate receptor antagonist (-)-6-phosphonomethyl-deca-hydroisoquinoline-3-carboxylic acid (LY235959) potentiates the antinociceptive effects of opioids that vary in efficacy at the mu-opioid receptor. J Pharmacol Exp Ther. 2003 Nov 1;307(2):785-92.
Allen RM, Granger AL, Dykstra LA. Dextromethorphan potentiates the antinociceptive effects of morphine and the delta-opioid agonist SNC80 in squirrel monkeys. J Pharmacol Exp Ther. 2002 Feb 1;300(2):435-41.